Top

Published in:

01-05-2019 | Breast Cancer | Preclinical study

ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness

Authors: Yin Liu, Puspa R. Pandey, Sambad Sharma, Fei Xing, Kerui Wu, Amar Chittiboyina, Shih-Ying Wu, Abhishek Tyagi, Kounosuke Watabe

Published in: Breast Cancer Research and Treatment | Issue 1/2019

Abstract

Purpose

Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer which could progress to or recur as invasive breast cancer. The underlying molecular mechanism of DCIS progression is yet poorly understood, and appropriate biomarkers to distinguish benign form of DCIS from potentially invasive tumor are urgently needed.

Methods

To identify the key regulators of DCIS progression, we performed gene-expression analysis of syngeneic breast cancer cell lines MCF10A, DCIS.com, and MCF10CA and cross-referenced the targets with patient cohort data.

Results

We identified ID2 as a critical gene for DCIS initiation and found that ID2 promoted DCIS formation by enhancing cancer stemness of pre-malignant cells. ID2 also plays a pivotal role in survival of the aggressive cancer cells. In addition, we identified INHBA and GJB2 as key regulators for the transition of benign DCIS to aggressive phenotype. These two genes regulate migration, colonization, and stemness of invasive cancer cells. Upregulation of ID2 and GJB2 predicts poor prognosis after breast-conserving surgery. Finally, we found a natural compound Helichrysetin as ID2 inhibitor which suppresses DCIS formation in vitro and in vivo.

Conclusion

Our results indicate that ID2 is a key driver of DCIS formation and therefore is considered to be a potential target for prevention of DCIS, while INHBA and GJB2 play vital roles in progression of DCIS to IDC and they may serve as potential prognosis markers.

Available only for authorised users

Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Land SR, Margolese RG, Swain SM, Costantino JP et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103(6):478–488CrossRefPubMedPubMedCentral

Howlader NNA, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2016) SEER Cancer Statistics Review, 1975–2014. National Cancer Institute, Bethesda, MD. https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017

Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD (2011) Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 12(1):21–29CrossRefPubMed

Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388CrossRefPubMed

Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361(9354):296–300CrossRefPubMed

Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ et al (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10(5):501–507CrossRefPubMed

Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC (1990) Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50(18):6075–6086PubMed

Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR (1996) MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 148(1):313–319PubMedPubMedCentral

Miller FR, Santner SJ, Tait L, Dawson PJ (2000) MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 92(14):1185–1186CrossRefPubMed

10.

Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, Wolman SR, Heppner GH, Miller FR (2001) Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 65(2):101–110CrossRefPubMed

11.

Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, Saito K, Commes T, Hayashi S, Watabe M et al (2003) The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res 63(8):1731–1736PubMed

12.

Balleine RL, Webster LR, Davis S, Salisbury EL, Palazzo JP, Schwartz GF, Cornfield DB, Walker RL, Byth K, Clarke CL et al (2008) Molecular grading of ductal carcinoma in situ of the breast. Clin Cancer Res 14(24):8244–8252CrossRefPubMedPubMedCentral

13.

Perk J, Iavarone A, Benezra R (2005) Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer 5(8):603–614CrossRefPubMed

14.

Stighall M, Manetopoulos C, Axelson H, Landberg G (2005) High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells. Int J Cancer 115(3):403–411CrossRefPubMed

15.

Itahana Y, Singh J, Sumida T, Coppe JP, Parrinello S, Bennington JL, Desprez PY (2003) Role of Id-2 in the maintenance of a differentiated and noninvasive phenotype in breast cancer cells. Cancer Res 63(21):7098–7105PubMed

16.

Li K, Yao L, Chen L, Cao ZG, Yu SJ, Kuang XY, Hu X, Shao ZM (2014) ID2 predicts poor prognosis in breast cancer, especially in triple-negative breast cancer, and inhibits E-cadherin expression. Onco Targets Ther 7:1083–1094PubMedPubMedCentral

17.

Becker-Herman S, Lantner F, Shachar I (2002) Id2 negatively regulates B cell differentiation in the spleen. J Immunol 168(11):5507–5513CrossRefPubMed

18.

Damdinsuren B, Nagano H, Kondo M, Yamamoto H, Hiraoka N, Yamamoto T, Marubashi S, Miyamoto A, Umeshita K, Dono K et al (2005) Expression of Id proteins in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Int J Oncol 26(2):319–327PubMed

19.

Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105–111CrossRefPubMed

20.

Castellana B, Escuin D, Peiro G, Garcia-Valdecasas B, Vazquez T, Pons C, Perez-Olabarria M, Barnadas A, Lerma E (2012) ASPN and GJB2 are implicated in the mechanisms of invasion of ductal breast carcinomas. J Cancer 3:175–183CrossRefPubMedPubMedCentral

21.

Ezumi K, Yamamoto H, Murata K, Higashiyama M, Damdinsuren B, Nakamura Y, Kyo N, Okami J, Ngan CY, Takemasa I et al (2008) Aberrant expression of connexin 26 is associated with lung metastasis of colorectal cancer. Clin Cancer Res 14(3):677–684CrossRefPubMed

22.

Okano M, Yamamoto H, Ohkuma H, Kano Y, Kim H, Nishikawa S, Konno M, Kawamoto K, Haraguchi N, Takemasa I et al (2013) Significance of INHBA expression in human colorectal cancer. Oncol Rep 30(6):2903–2908CrossRefPubMed

23.

Burger HG, Igarashi M (1988) Inhibin: definition and nomenclature, including related substances. Endocrinology 122(4):1701–1702CrossRefPubMed

24.

Thiagarajan PS, Sinyuk M, Turaga SM, Mulkearns-Hubert EE, Hale JS, Rao V, Demelash A, Saygin C, China A, Alban TJ et al (2018) Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nat Commun 9(1):578CrossRefPubMedPubMedCentral

25.

Rawlins EL, Clark CP, Xue Y, Hogan BL (2009) The Id2 + distal tip lung epithelium contains individual multipotent embryonic progenitor cells. Development 136(22):3741–3745CrossRefPubMedPubMedCentral

26.

Wong MV, Jiang S, Palasingam P, Kolatkar PR (2012) A divalent ion is crucial in the structure and dominant-negative function of ID proteins, a class of helix-loop-helix transcription regulators. PLoS ONE 7(10):e48591CrossRefPubMedPubMedCentral

27.

Wen XF, Chen M, Wu Y, Chen MN, Glogowska A, Klonisch T, Zhang GJ (2018) Inhibitor of DNA binding 2 inhibits epithelial-mesenchymal transition via up-regulation of Notch3 in breast cancer. Transl Oncol 11(5):1259–1270CrossRefPubMedPubMedCentral

28.

Kleeff J, Ishiwata T, Friess H, Buchler MW, Israel MA, Korc M (1998) The helix-loop-helix protein Id2 is overexpressed in human pancreatic cancer. Cancer Res 58(17):3769–3772PubMed

29.

Lasorella A, Boldrini R, Dominici C, Donfrancesco A, Yokota Y, Inserra A, Iavarone A (2002) Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res 62(1):301–306PubMed

30.

Coma S, Amin DN, Shimizu A, Lasorella A, Iavarone A, Klagsbrun M (2010) Id2 promotes tumor cell migration and invasion through transcriptional repression of semaphorin 3F. Cancer Res 70(9):3823–3832CrossRefPubMedPubMedCentral

31.

Lofstedt T, Jogi A, Sigvardsson M, Gradin K, Poellinger L, Pahlman S, Axelson H (2004) Induction of ID2 expression by hypoxia-inducible factor-1: a role in dedifferentiation of hypoxic neuroblastoma cells. J Biol Chem 279(38):39223–39231CrossRefPubMed

32.

Isenmann S, Arthur A, Zannettino AC, Turner JL, Shi S, Glackin CA, Gronthos S (2009) TWIST family of basic helix-loop-helix transcription factors mediate human mesenchymal stem cell growth and commitment. Stem Cells 27(10):2457–2468CrossRefPubMed

33.

Izumi N, Mizuguchi S, Inagaki Y, Saika S, Kawada N, Nakajima Y, Inoue K, Suehiro S, Friedman SL, Ikeda K (2006) BMP-7 opposes TGF-beta1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. Am J Physiol Lung Cell Mol Physiol 290(1):L120–L126CrossRefPubMed

34.

Zhu T, Gao YF, Chen YX, Wang ZB, Yin JY, Mao XY, Li X, Zhang W, Zhou HH, Liu ZQ (2017) Genome-scale analysis identifies GJB2 and ERO1LB as prognosis markers in patients with pancreatic cancer. Oncotarget 8(13):21281–21289CrossRefPubMedPubMedCentral

35.

Kim H, Watkinson J, Varadan V, Anastassiou D (2010) Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1. BMC Med Genomics 3:51CrossRefPubMedPubMedCentral

36.

Wang Q, Wen YG, Li DP, Xia J, Zhou CZ, Yan DW, Tang HM, Peng ZH (2012) Upregulated INHBA expression is associated with poor survival in gastric cancer. Med Oncol 29(1):77–83CrossRefPubMed

37.

Mom CH, Engelen MJ, Willemse PH, Gietema JA, ten Hoor KA, de Vries EG, van der Zee AG (2007) Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort. Gynecol Oncol 105(2):365–372CrossRefPubMed

38.

Robertson DM, Pruysers E, Jobling T (2007) Inhibin as a diagnostic marker for ovarian cancer. Cancer Lett 249(1):14–17CrossRefPubMed

39.

Burger HG, Dudley EC, Hopper JL, Groome N, Guthrie JR, Green A, Dennerstein L (1999) Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 84(11):4025–4030PubMed

40.

Chen Q, Boire A, Jin X, Valiente M, Er EE, Lopez-Soto A, Jacob L, Patwa R, Shah H, Xu K et al (2016) Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 533(7604):493–498CrossRefPubMedPubMedCentral

41.

Friedl P, Gilmour D (2009) Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol 10(7):445–457CrossRefPubMed

Title: ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness
Authors: Yin Liu
Puspa R. Pandey
Sambad Sharma
Fei Xing
Kerui Wu
Amar Chittiboyina
Shih-Ying Wu
Abhishek Tyagi
Kounosuke Watabe
Publication date: 01-05-2019
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 1/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-05126-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk

Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases

Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction

Efficacy of self-administered complex decongestive therapy on breast cancer-related lymphedema: a single-blind randomized controlled trial

HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment

Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer